Patents by Inventor Matthias Habjan

Matthias Habjan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA
    Patent number: 11723964
    Abstract: The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: August 15, 2023
    Assignee: Bavarian Nordic A/S
    Inventors: Hubertus Hochrein, Henning Lauterbach, José Medina Echeverz, Matthias Habjan
  • A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease
    Publication number: 20230233670
    Abstract: The invention relates to a recombinant Modified Vaccinia Virus Ankara (MVA) encoding a spike (S) protein or a part thereof, such as a receptor-binding domain (RBD), and additional antigenic sequences derived from other proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease 19 (COVID-19).
    Type: Application
    Filed: June 10, 2021
    Publication date: July 27, 2023
    Applicant: Bavarian Nordic A/S
    Inventors: Jürgen Hausmann, Robin Steigerwald, Matthias Habjan, José Medina Echeverz, Stephan Rambichler
  • Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
    Publication number: 20230190922
    Abstract: The invention relates to a composition and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The composition comprises a recombinant MVA encoding a Tumor Associated Antigen (“TAA”) as well as 4-1BBL and/or CD40L and can be administered to a subject in any suitable manner, including by intravenous and/or intratumoral administration.
    Type: Application
    Filed: November 20, 2020
    Publication date: June 22, 2023
    Applicant: Bavarian Nordic A/S
    Inventors: Henning Lauterbach, Maria Hinterberger, José Medina Echeverz, Matthias Habjan, Jürgen Hausmann, Markus Kalla
  • Combination Therapy for Treating Cancer With an Antibody and Intravenous Administration of a Recombinant MVA
    Publication number: 20220249636
    Abstract: The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient.
    Type: Application
    Filed: March 14, 2022
    Publication date: August 11, 2022
    Applicant: Bavarian Nordic A/S
    Inventors: Hubertus HOCHREIN, Henning LAUTERBACH, José MEDINA ECHEVERZ, Matthias HABJAN
  • Combination therapy for treating cancer with an intravenous administration of a recombinant MVA and an antibody
    Patent number: 11273211
    Abstract: The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: March 15, 2022
    Assignee: Bavarian Nordic A/S
    Inventors: Hubertus Hochrein, Henning Lauterbach, José Medina Echeverz, Matthias Habjan
  • Combination Therapy for Treating Cancer with an Intravenous Administration of a Recombinant MVA and an Antibody
    Publication number: 20200306352
    Abstract: The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient.
    Type: Application
    Filed: August 23, 2018
    Publication date: October 1, 2020
    Applicant: Bavarian Nordic A/S
    Inventors: Hubertus Hochrein, Henning Lauterbach, José Medina Echeverz, Matthias Habjan
  • RIFT VALLEY FEVER VIRUS-LIKE PARTICLES AND THEIR USE FOR IMMUNIZATION AND AS TEST SYSTEM
    Publication number: 20110110976
    Abstract: Disclosed is a method for producing virus-like particles (VLP) that comprises the steps of (a) transfecting a mammalian cell line with several independent vectors, including (1) a vector containing at least a substantial part of the M gene from Rift Valley Fever Virus, (2) a vector containing at least a substantial part of the L gene from Rift Valley Fever Virus, (3) a vector containing at least a substantial part of the N gene from Rift Valley Fever Virus and (4) a vector containing a multicloning site flanked by the non-coding 5?- and 3?-ends of the L-, M- or S-segment of Rift Valley Fever Virus, and (b) culturing the transfected mammalian cell line under suitable conditions and obtaining the VLPs from the supernatant of the transfected cultured cell lines. The so-obtained VLPs can be used for vaccination and in methods for testing the antiviral activity of compounds.
    Type: Application
    Filed: June 9, 2009
    Publication date: May 12, 2011
    Applicant: Universitaetsklinikum Freiburg
    Inventors: Friedemann Weber, Matthias Habjan, Martin Spiegel, Nicola Penski